# EDGAR Filing Document

**Accession Number:** 0001973056
**File Stem:** 0001641172-25-016871
**Filing Date:** 2025-6
**Character Count:** 12468
**Document Hash:** f6f579a39a5cbf71bf885d9f38212fb0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-016871.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001641172-25-016871

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250626

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bowen Acquisition Corp
- **CENTRAL INDEX KEY:** 0001973056
- **STANDARD INDUSTRIAL CLASSIFICATION:** SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41741
- **FILM NUMBER:** 251086126

**BUSINESS ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVE, SUITE 2446
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170
- **BUSINESS PHONE:** 203-998-5540

**MAIL ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVE, SUITE 2446
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): <u>June 26, 2025</u>

**<u>BOWEN ACQUISITION CORP</u>**

(Exact Name of Registrant as Specified in Charter)

<u>Cayman Islands</u> <u>001-41741</u> <u>N/A 00-0000000</u> <br> (State or Other Jurisdiction (Commission (IRS Employer <br> of Incorporation) File Number) Identification No.)

420 Lexington Ave, Suite 2446

New York, NY 10170

(Address of Principal Executive Offices) (Zip Code)

(203) 998-5540

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Units, each consisting of one ordinary share and one right | BOWNU | The Nasdaq Stock Market LLC |
| Ordinary Shares, par value $0.0001 per share | BOWN | The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to one-tenth of one ordinary share upon the completion of the Company's initial business combination | BOWNR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

On June 26, 2025, Bowen Acquisition Corp, a Cayman Islands exempted company (the "Company"), entered into a second amendment (the "Amendment") to the previously disclosed Agreement and Plan of Reorganization, dated as of January 18, 2024 and amended on March 21, 2025 ("Merger Agreement"), by and among the Company, Bowen Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of the Company ("Merger Sub"), Shenzhen Qianzhi BioTechnology Co. Ltd., a company incorporated in the People's Republic of China and a wholly owned subsidiary of NewCo (as defined below) ("Qianzhi"), and Qianzhi Group Holding (Cayman) Limited, a newly formed Cayman Islands company ("NewCo"). As previously disclosed, the Merger Agreement contemplates that Merger Sub will merge with and into NewCo, with NewCo being the surviving company of the merger and becoming a wholly owned subsidiary of the Company.

The Amendment extends the outside date by which the parties must consummate the Merger Agreement to December 14, 2025.

The foregoing description of the Amendment is qualified in its entirety by reference to the text of the Amendment, a copy of which is attached as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 2.1 | [Amendment No. 2 to Agreement and Plan of Reorganization](ex2-1.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

**<u>Cautionary Note Regarding Forward Looking Statements</u>**

Neither the Company nor any of its affiliates makes any representation or warranty as to the accuracy or completeness of the information contained in this Current Report on Form 8-K. This Current Report on Form 8-K is not intended to be all-inclusive and is not intended to form the basis of any investment decision or any other decision in respect of the Company or the proposed business combination with NewCo and Qianzhi.

This Current Report on Form 8-K include "forward-looking statements" made pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements generally are identified by the words or phrases such as "aspire," "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "will be," "will continue," "will likely result," "could," "should," "believe(s)," "predicts," "potential," "continue," "future," "opportunity," seek," "intend," "strategy," or the negative version of those words or phrases or similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and anticipated financial impacts of the proposed business combination with NewCo and Qianzhi.

The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

**<u>No Offer or Solicitation</u>**

This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: June 27, 2025 |  |  |
|  | By: | */s/ Jiangang Luo* |
|  |  | Jiangang Luo |
|  |  | Chief Executive Officer |

---

## Exhibit 2.1

**Exhibit 2.1**

**AMENDMENT NO. 2 TO**

**AGREEMENT AND PLAN OF REORGANIZATION**

This Amendment No. 2 to the Agreement and Plan of Reorganization is entered into as of June 26, 2025 by and among Bowen Acquisition Corp. ("Bowen"), Bowen Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Bowen ("Merger Sub"), Shenzhen Qianzhi BioTechnology Co. Ltd., a company incorporated in the People's Republic of China and a wholly owned subsidiary of NewCo (as defined below) ("Qianzhi"), and Qianzhi Group Holding (Cayman) Limited, a newly formed Cayman Islands company ("NewCo"). Each of Bowen, Merger Sub, Qianzhi and NewCo are referred to herein, individually, as a "<u>Party</u>" and, collectively, as the "<u>Parties</u>".

WHEREAS, the Parties entered into that certain Agreement and Plan of Reorganization, dated as of January 18, 2024 (the "Original Agreement"), which, among other things, generally provided that the Original Agreement could be terminated by either Bowen or Qianzhi if the Merger (as defined in the Original Agreement) had not been consummated by December 31, 2024 (the "Original Outside Date"); and

WHEREAS, on March 21, 2025, the Parties amended the Original Agreement (as amended, the "Amended Agreement") to provide that the Original Outside Date would be extended from December 31, 2024 to July 14, 2025 (the "Amended Outside Date"); and

WHEREAS, the Parties now desire to further extend the Amended Outside Date from July 14, 2025 to December 14, 2025;

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Amendment to Amended Agreement</u>. Section 8.1(b) of the Amended Agreement is hereby amended such that the text "July 14, 2025" contained in such section is deleted and the text "December 14, 2025" is inserted therefor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Interpretation</u>. Capitalized terms not defined herein shall have the meaning ascribed to them in the Amended Agreement. On and after the date hereof, each reference in the Amended Agreement to "this Agreement", "hereunder", "hereof", "herein" or words of like import referring to the Amended Agreement shall mean and be a reference to the Amended Agreement as amended by this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>No Further Amendments</u>. Except as expressly set forth herein, the Amended Agreement shall remain in full force and effect. This Amendment may not be amended or modified except pursuant to a written agreement by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Counterparts</u>. This Amendment may be executed by the Parties in counterpart, and the executed counterparts shall be deemed by the Parties as a single executed and binding document and may be delivered by email or facsimile to the Parties and their counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Miscellaneous</u>. The provisions of Article X (General Provisions) of the Amended Agreement are incorporated herein, *mutatis mutandis*.

 

[*Remainder of Page Intentionally Left Blank*]

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first written above.

---

| | |
|:---|:---|
| BOWEN ACQUISITION CORP | BOWEN ACQUISITION CORP |
| By: | */s/ Jiangang Luo* |
| Name: | Jiangang Luo |
| Title: | CEO |

---

---

| | |
|:---|:---|
| BOWEN MERGER SUB | BOWEN MERGER SUB |
| By: | */s/ Na Gai* |
| Name: | Na Gai |
| Title: | Director |

---

---

| | |
|:---|:---|
| SHENZHEN QIANZHI BIOTECHNOLOGY CO., LTD | SHENZHEN QIANZHI BIOTECHNOLOGY CO., LTD |
| By: | */s/ Juxiang Hu* |
| Name: | Juxiang Hu |
| Title: | Legal Representative |

---

---

| | |
|:---|:---|
| QIANZHI GROUP HOLDING (CAYMAN) LIMITED | QIANZHI GROUP HOLDING (CAYMAN) LIMITED |
| By: | */s/ Xiaoqin Lin* |
| Name: | Xiaoqin Lin |
| Title: | Director |

---